Where are we now: Assessing the price, availability and affordability of essential medicines in Delhi as India plans free medicine for all

BMC Health Services Research

Volumn 13, Issue 1, 2013, Pages

  Kotwani, Anita ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

Access; Affordability; Essential medicines; Generic medicines; Medicine availability; Medicine price; Private retail pharmacies; Procurement price; Public sector

Indexed keywords

ESSENTIAL DRUG;

ARTICLE; CLASSIFICATION; ECONOMICS; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH CARE SURVEY; HUMAN; INDIA; INSURANCE; ORGANIZATION AND MANAGEMENT;

DRUGS, ESSENTIAL; HEALTH CARE SURVEYS; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; INDIA; PRIVATE SECTOR; PUBLIC SECTOR; UNIVERSAL COVERAGE;

EID: 84880939063     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-13-285     Document Type: Article

References (42)

1. Essential medicines and human rights: what can they learn from each other? Hogerzeil H, Bull World Health Organ 2006 84 371 375 10.2471/BLT.06. 031153 16710546
2. Access to essential medicines in national constitutions. Perehudoff SK, Laing RO, Hogerzeil HV, Bull World Health Organ 2010 88 800 10.2471/BLT.10. 078733 21076556
3. High level expert group report on universal health coverage for India 2011 Available at http://planningcommission.nic.in/reports/genrep/rep-uhc0812. pdf. [Accessed on August 17, 2012]
4. Sinha K, Free medicines for all from October. Article in Times of India 2012 http://articles.timesofindia.indiatimes.com/2012-06-23/india/32381413-1- health-centres-essential-drugs-list-free-medicines
5. Health systems financing and the path to universal coverage. Evans DB, Etienne C, Bull World Health Organ 2010 88 402 10.2471/BLT.10.078741 20539847
6. The Millennium Development Goals report New York: United Nations 2009 Available at http://www.un.org/millenniumgoals/pdf/MDG-Report-2009-ENG.pdf
7. Evaluating pharmaceuticals for health policy in low- and middle-income country settings. Creese A, Kotwani A, Kutzin J, Pillay A, Evaluating pharmaceuticals for health policy and reimbursement Massachusetts, U.S.A: Blackwell Publishing (in collaboration with WHO, Geneva), Freemantle N, Hill S, 2004 227 243
8. Measuring medicine prices, availability, affordability and price components Geneva: World Health Organization & Health Action International 2 2008 Available from: http://www.haiweb.org/medicineprices/manual/documents.html [accessed 4 August 2011]
9. Measuring medicine prices in Peru: validation of key aspects of WHO/HAI survey methodology. Madden JM, Meza E, Ewen M, Laing RO, Stephens P, Ross-Degnan D, Rev Panam Salud Publica 2010 27 291 299 10.1590/S1020-49892010000400008 20512232
10. Kotwani A, Levison L, Price components and access to medicines in Delhi, India Project Report 2007 Available at: http://www.healthpolicy.cn/rdfx/jbywzd/ gjjy2/yd/yjwx/201002/P020100227572262042149.pdf [Accessed on 4 August 2012]
11. A comparative evaluation of price and quality of some branded versus branded-generic medicines of the same manufacturer in India. Singal G, Nanda A, Kotwani A, Ind J Pharmacol 2011 43 131 136 10.4103/0253-7613.77344
12. What is a median price ratio? Madden J, Essential Drug Monitor 2003 33 17
13. Cambridge MA, International Drug Price Indicator Guide, Management Sciences for Health 2011 http://erc.msh.org/dmpguide/index.cfm?search-cat= yes&display=yes&module=dmp&language=english&year=2010 [Accessed July 13, 2011]
14. Gelders S, Ewen M, Noguchi N, Laing R, Price, availability and affordability. An international comparison of chronic disease medicines Cairo: World health Organization and Health Acton International 2006 http://www.haiweb.org/GlobalDatabase/Main.htm
15. Medicine prices and availability at six sites in India: using the WHO-HAI methodology. Kotwani A, Ewen M, Dey D, et al. Ind J Med Res 2007 125 645 654 (Pubitemid 47180968)
16. Quality medicines for the poor: experience of the Delhi programme on rational use of drugs. Chaudhury RR, Parameswar R, Gupta U, Sharma S, Tekur U, Bapna JS, HPP 2005 20 124 136 (Pubitemid 40395685)
17. Insights for policymakers from a medicine price survey in Rajasthan. Kotwani A, Gurbani N, Sharma S, Chaudhury R, Ind J Med Res 2009 129 451 454
18. Transparency and accountability in public procurement of essential medicines in developing countries. Kotwani A, IJUDH 2011 1 15 30
19. Plan M-TS. 2008-2013 [Internet] Geneva: World Health Organization 2008 Available from: http://apps.who.int/gb/e/e-amtsp.html [accessed 13 July 2011]
20. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R, Lancet 2009 373 240 249 10.1016/S0140-6736(08)61762-6 19042012
21. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. Babar ZUD, Ibrahim MIM, Singh H, Bukahri NI, Creese A, PLoS Med 2007 4 466 475 (Pubitemid 46495314)
22. Prices, availability and affordability of essential medicines in rural areas of Hubei Province. Yang H, Dib HH, Zhu M, Qi G, Zhang X, HPP 2010 25 219 229
23. Availability, price, and affordability of asthma medicines in five Indian states. Kotwani A, Intern J Tuber Lung Dis 2009 13 574 579
24. National list of essential medicines of India 2011 Available at: http://www.cdsco.nic.in/ [Accessed on 4 August 2012]
25. Psychiatric medicines in India: why public healthcare facilities and a thriving generics industry cannot assure access and affordability. Kotwani A, Internl Psychiatry 2012 9 34 36
26. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Mendis S, Fukino K, Cameron A, Laing R, Filipe A Jr, Khatib O, et al. Bull World Health Organ 2007 85 279 288 10.2471/BLT.06.033647 17546309 (Pubitemid 46556727)
27. The current availability of antiepileptic drugs in Zambia: implications for the ILAE/WHO "out of the shadows" campaign. Chomba EN, Haworth A, Mbewe E, Atadzhanov M, Ndubani P, Kansembe H, et al. AmJTrop Med Hyg 2010 83 571 574 10.4269/ajtmh.2010.10-0100
28. Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. Van Mourik MS, Cameron A, Ewen M, Laing RO, BMC Cardiovasc Disord 2010 10 25 10.1186/1471-2261-10-25 20534118
29. Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Cameron A, Roubos I, Ewen M, Mantel-Teeuwisse A, Leufkens H, Laing R, Bull World Health Organ 2011 89 412 421 10.2471/BLT.10.084327 21673857
30. Diarrhoea Treatment Guidelines including new recommendations for the use of ORS and zinc supplementation for Clinic-Based Healthcare Workers WHO, UNICEF, USAID 2005 Available at: http://whqlibdoc.who.int/publications/2005/a85500.pdf [Accessed 13 August 2012]
31. Ensuring access to essential medicines in the developing countries: a framework for action. Quick JD, CPT 2003 73 279 283 (Pubitemid 36403587)
32. Combating inappropriate use of medicines. Holloway K, Expert Rev Clin Pharmacol 2011 4 335 348 10.1586/ecp.11.14 22114780
33. Tracking medicine prices in the supply chain: who really benefits from the free market in India? Kotwani A, Econ Pol Wkly 2013 Accepted for publication
34. Department of Pharmaceuticals, Ministry of Chemicals and fertilizers, Government of India 2012 http://www.pharmaceuticals.gov.in [Accessed on 17 August 2012]
35. The World Bank, GNI per capita, Atlas method (current US$) 2013 Available at http://data.worldbank.org/indicator/NY.GNP.PCAP.CD [Accessed on 24 April 2013]
36. India Watch-i watch 2012 Available at http://www.wakeupcall.org/ administration-in-india/poverty-line.php. [Accessed on 17 August 2012]
37. Indian health: the path from crisis to progress. Horton R, Das P, Lancet 2011 377 181 183 10.1016/S0140-6736(10)62179-4 21227502
38. Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing world. Niëns LM, Cameron A, Van de Poel E, Ewen M, Brouwer WBF, Laing R, PLoS Med 2010 7 1 8
39. Competition in off-patent drug markets: Issues regulation and evidence. Kanavos P, Costa-Font J, Seeley E, Economic Policy 2008 23 499 544 10.1111/j.1468-0327.2008.00207.x
40. Experiences with generics. Joncheere K, Rietveld AH, Huttin C, Drugs and Money The Netherlands: Published on behalf of WHO-Europe, Dukes FM, Haaijer-Ruskamp CP, Joncheere A, Rietveld H, 7 2002 101 110 IOS Press
41. Cameron A, Ewen M, Auton M, Abegunde D, The world medicines situation 2011. Medicine prices, availability and affordability http://www.who.int/ medicines/areas/policy/world-medicines-situation/WMS-ch6-wPricing-v6.pdf
42. Sound price data-sound price policies. Ewen M, Essential drug monitor 2003 33 23